Ranitidine

Generic Name: Ranitidine

Brand Names: Good Sense Acid Reducer, Wal-zan, Zantac

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₂N_₄O_₃S

CAS Number: 66357-35-5

Unique Ingredient Identifier: 884KT10YB7

Background: Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.

The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.

Indication: This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastric ulcers and maintenance therapy of gastric ulcers at a reduced dose. In addition to the above, ranitidine can be used for the treatment of GERD symptoms, treatment of erosive esophagitis (endoscopically diagnosed) and the maintenance of gastric or duodenal ulcer healing.

Associated Conditions: Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Clinical Trials

Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ranitidine hydrochloride ODT
Drug: Ranitidine hydrochloride ODT RM
Drug: Ranitidine hydrochloride

First Posted Date: 2014-07-21

Last Posted Date: 2014-07-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 42

Registration Number: NCT02195804

Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ranitidine + Tiotropium
Drug: Cimetidine + Tiotropium
Drug: Tiotropium

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02172417

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS
Drug: Ranitidine

First Posted Date: 2014-06-23

Last Posted Date: 2014-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02170792

The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux

Phase 4

Withdrawn

Conditions: Eustachian Tube Dysfunction
Laryngopharyngeal Reflux

Interventions: Drug: Omeprazole
Drug: Ranitidine
Drug: Pantoprazole
Procedure: 24-Hour Diagnostic pH-Probe Test
Procedure: Laryngoscopy

First Posted Date: 2014-04-25

Last Posted Date: 2016-09-26

Lead Sponsor: Loma Linda University

Registration Number: NCT02123498

Locations: 🇺🇸
1895 Orange Tree Lane, Suite 102, Redlands, California, United States
🇺🇸
11234 Anderson Street, Loma Linda, California, United States